6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Neurochemical Imbalance in Substance Use Disorders
Substance use disorders (SUDs) are closely linked to neurochemical imbalances in the brain. Drugs and alcohol disrupt normal neurotransmitter activity, particularly dopamine, serotonin, and glutamate systems. This dysregulation contributes to cravings, withdrawal symptoms, and compulsive substance-seeking behaviors. Chronic use alters brain reward pathways, making natural rewards less satisfying and perpetuating addiction cycles. Addressing these imbalances often requires a combination of pharmacotherapy, such as medications that stabilize neurotransmitter levels, and behavioral interventions like CBT. Understanding the neurochemical underpinnings of SUDs enables clinicians to tailor treatments, improving recovery outcomes and reducing relapse risks.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States